Dr. Joy Derwenskus, DO

Neurology Nashville, TN Female
NPI: 1316937915
Total Payments
$289,451
2024 Payments
$18.88
Companies
36
Transactions
635
Medicare Patients
1,202
Medicare Billing
$95,686

Payment Breakdown by Category

Other$182,633 (63.1%)
Consulting$78,504 (27.1%)
Food & Beverage$13,133 (4.5%)
Travel$12,472 (4.3%)
Research$2,105 (0.7%)
Education$602.93 (0.2%)

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $182,633 76 63.1%
Consulting Fee $78,504 19 27.1%
Food and Beverage $13,133 471 4.5%
Travel and Lodging $12,472 43 4.3%
Unspecified $2,105 8 0.7%
Education $602.93 18 0.2%

Payments by Type

General
$287,346
627 transactions
Research
$2,105
8 transactions

Top Paying Companies

Company Total Records Latest Year
Biogen, Inc. $69,317 73 $0 (2022)
GENZYME CORPORATION $51,868 86 $0 (2024)
Teva Pharmaceuticals USA, Inc. $48,707 95 $0 (2019)
EMD Serono, Inc. $45,080 133 $0 (2021)
Genentech USA, Inc. $31,420 62 $0 (2019)
Novartis Pharmaceuticals Corporation $17,695 44 $0 (2019)
Bayer HealthCare Pharmaceuticals Inc. $13,052 9 $0 (2018)
Celgene Corporation $8,408 16 $0 (2020)
TG THERAPEUTICS, INC. $1,657 3 $0 (2023)
Amgen Inc. $506.85 7 $0 (2022)

Payment History by Year

Year Amount Transactions Top Company
2024 $18.88 1 GENZYME CORPORATION ($18.88)
2023 $1,678 4 TG THERAPEUTICS, INC. ($1,657)
2022 $179.55 2 Amgen Inc. ($119.55)
2021 $34.41 1 EMD Serono, Inc. ($34.41)
2020 $8,780 17 Celgene Corporation ($7,504)
2019 $95,404 207 Biogen, Inc. ($39,437)
2018 $102,404 242 Biogen, Inc. ($29,564)
2017 $80,953 161 Teva Pharmaceuticals USA, Inc. ($26,882)

All Payment Transactions

635 individual payment records from CMS Open Payments — Page 1 of 26

Date Company Product Nature Form Amount Type
05/31/2024 GENZYME CORPORATION — Food and Beverage In-kind items and services $18.88 General
10/19/2023 TG Therapeutics, Inc. BRIUMVI (Drug) Consulting Fee Cash or cash equivalent $1,500.00 General
Category: Immunology
10/13/2023 GENZYME CORPORATION — Food and Beverage In-kind items and services $20.72 General
10/12/2023 TG THERAPEUTICS, INC. BRIUMVI (Drug) Food and Beverage In-kind items and services $124.50 General
Category: Immunology
10/11/2023 TG Therapeutics, Inc. BRIUMVI (Drug) Food and Beverage In-kind items and services $32.31 General
Category: Immunology
11/18/2022 Amgen Inc. Aimovig (Biological) Food and Beverage In-kind items and services $119.55 General
Category: Neuroscience
09/06/2022 Biogen, Inc. TYSABRI (Biological) Education In-kind items and services $60.00 General
Category: Neurology
04/20/2021 EMD Serono, Inc. — Food and Beverage In-kind items and services $34.41 General
12/02/2020 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Education Cash or cash equivalent $14.88 General
Category: Neuroscience
12/02/2020 E.R. Squibb & Sons, L.L.C. ZEPOSIA (Drug) Education Cash or cash equivalent $14.88 General
Category: Neuroscience
07/29/2020 Celgene Corporation ZEPOSIA (Drug) Education Cash or cash equivalent $8.69 General
Category: Neuroscience
07/29/2020 Celgene Corporation ZEPOSIA (Drug) Education Cash or cash equivalent $8.69 General
Category: Neuroscience
07/09/2020 EMD Serono, Inc. Mavenclad (Drug) Food and Beverage In-kind items and services $22.51 General
Category: Neurology
03/31/2020 GENZYME CORPORATION LEMTRADA (Biological) — In-kind items and services $129.92 Research
Study: An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab • Category: Neurology
03/03/2020 EMD Serono, Inc. Mavenclad (Drug) Food and Beverage In-kind items and services $108.79 General
Category: Neurology
02/27/2020 EMD Serono, Inc. Mavenclad (Drug) Food and Beverage In-kind items and services $104.70 General
Category: Neurology
02/03/2020 EMD Serono, Inc. Mavenclad (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $860.00 General
Category: Neurology
02/01/2020 Celgene Corporation ZEPOSIA (Drug) Consulting Fee Cash or cash equivalent $6,820.00 General
Category: Neuroscience
02/01/2020 Celgene Corporation ZEPOSIA (Drug) Travel and Lodging Cash or cash equivalent $249.32 General
Category: Neuroscience
02/01/2020 Celgene Corporation ZEPOSIA (Drug) Travel and Lodging Cash or cash equivalent $233.96 General
Category: Neuroscience
02/01/2020 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $59.42 General
Category: Neuroscience
02/01/2020 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $54.69 General
Category: Neuroscience
02/01/2020 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $39.84 General
Category: Neuroscience
02/01/2020 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $29.71 General
Category: Neuroscience
01/07/2020 Lundbeck LLC NORTHERA (Drug) Food and Beverage Cash or cash equivalent $19.55 General
Category: NEUROLOGY
123…26»

Research Studies & Clinical Trials

Study Name Company Amount Records
A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) GENZYME CORPORATION $1,228 4
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab GENZYME CORPORATION $744.07 3
A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study GENZYME CORPORATION $133.16 1

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 5 309 373 $136,824 $26,166
2022 4 309 354 $125,995 $23,501
2021 5 316 375 $138,402 $27,463
2020 3 268 295 $100,310 $18,557
Total Patients
1,202
Total Services
1,397
Medicare Billing
$95,686
Procedure Codes
28

All Medicare Procedures & Services

28 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 93 129 $41,022 $8,279 20.2%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2023 41 44 $18,876 $4,295 22.8%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 60 67 $21,306 $4,159 19.5%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2023 37 37 $18,204 $3,455 19.0%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2023 27 27 $13,284 $2,422 18.2%
64615 Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face Office 2023 12 27 $15,228 $1,893 12.4%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2023 23 24 $5,088 $924.91 18.2%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 16 18 $3,816 $739.16 19.4%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 94 123 $39,114 $7,206 18.4%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 39 43 $18,447 $4,014 21.8%
99204 New patient office or other outpatient visit, 45-59 minutes Office 2022 43 43 $21,156 $3,548 16.8%
99204 New patient office or other outpatient visit, 45-59 minutes Facility 2022 39 39 $19,188 $3,392 17.7%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 47 53 $16,854 $3,063 18.2%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 32 33 $6,996 $1,486 21.2%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 15 20 $4,240 $791.55 18.7%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 81 112 $35,616 $7,356 20.7%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 52 74 $23,532 $4,805 20.4%
99204 New patient outpatient visit, total time 45-59 minutes Facility 2021 49 49 $24,108 $4,665 19.4%
99215 Established patient outpatient visit, total time 40-54 minutes Office 2021 38 42 $18,018 $4,009 22.3%
99204 New patient outpatient visit, total time 45-59 minutes Office 2021 41 41 $20,172 $3,945 19.6%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 43 45 $9,540 $1,811 19.0%
99205 New patient outpatient visit, total time 60-74 minutes Office 2021 12 12 $7,416 $871.81 11.8%
99204 New patient office or other outpatient visit, typically 45 minutes Office 2020 77 77 $35,259 $6,235 17.7%
99204 New patient office or other outpatient visit, typically 45 minutes Facility 2020 51 51 $22,964 $4,743 20.7%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 38 48 $14,367 $2,677 18.6%
12»

About Dr. Joy Derwenskus, DO

Dr. Joy Derwenskus, DO is a Neurology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2005. The National Provider Identifier (NPI) number assigned to this provider is 1316937915.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joy Derwenskus, DO has received a total of $289,451 in payments from pharmaceutical and medical device companies, with $18.88 received in 2024. These payments were reported across 635 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($182,633).

As a Medicare-enrolled provider, Derwenskus has provided services to 1,202 Medicare beneficiaries, totaling 1,397 services with total Medicare billing of $95,686. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.

Practice Information

  • Specialty Neurology
  • Location Nashville, TN
  • Active Since 10/25/2005
  • Last Updated 03/30/2022
  • Taxonomy Code 2084N0400X
  • Entity Type Individual
  • NPI Number 1316937915

Products in Payments

  • AUBAGIO (Drug) $49,466
  • TECFIDERA (Drug) $49,037
  • COPAXONE (Drug) $40,726
  • OCREVUS (Biological) $31,269
  • Rebif (Biological) $28,370
  • GILENYA (Drug) $16,551
  • Mavenclad (Biological) $15,357
  • Betaseron (Drug) $13,052
  • TYSABRI (Biological) $9,586
  • AJOVY (Drug) $7,650
  • ZEPOSIA (Drug) $7,534
  • LEMTRADA (Drug) $2,213
  • BRIUMVI (Drug) $1,657
  • Mavenclad (Drug) $1,096
  • Ozanimod (Drug) $903.36
  • Aimovig (Biological) $404.58
  • APTIOM (Drug) $342.96
  • AIMOVIG (Biological) $235.42
  • NORTHERA (Drug) $193.31
  • MAYZENT (Drug) $164.67

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Neurology Doctors in Nashville

Jesus Pina-Garza, Md, MD

Neurology — Payments: $1.7M

Neurology $1.7M

Harold Moses, Md, MD

Neurology — Payments: $691,189

Neurology $691,189

Michael Froehler, M.d, M.D

Neurology — Payments: $419,665

Neurology $419,665

Daniel Claassen, M.d, M.D

Neurology — Payments: $418,370

Neurology $418,370

Amanda Peltier, Md, MD

Neurology — Payments: $264,466

Neurology $264,466

Dr. Samir Bangalore, Md, MD

Neurology — Payments: $141,277

Neurology $141,277